p53 protein expression patterns associated with TP53 mutations in breast carcinoma
Authors:
Open Access
- 20 June 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (1) , 213-222
Abstract
Purpose: The importance of a TP53 mutation has been demonstrated in several tumor types, including breast cancer (BC). However, the accuracy of p53 protein expression as a predictor of gene mutation has not been well studied in BC. Therefore, we evaluated p53 protein expression associated with TP53 mutations in breast cancers from 64 patients. Methods: TP53 mutation was examined using next-generation sequencing (NGS). p53 protein expression was examined using immunohistochemistry (IHC). Results: Among the 64 BCs, 55% demonstrated abnormal expression patterns including 27% overexpression, 22% null, 6% equivocal with 45% having a wild-type pattern. A TP53 mutation was present in 53% (34/64) of tumors including 30% (19/64) demonstrating a missense mutation, 11% (7/64) with a frameshift mutation, 11% (7/64) with a nonsense mutation, and 3% (1/64) with a splice site mutation. Abnormal expression of p53 protein was present in 33 of 34 (97%) tumors carrying a TP53 mutation; conversely, a wild-type pattern was present in 28 of 30 (93%) tumors without a detectable mutation (p < 0.0001). The majority of BCs with a p53 IHC overexpression pattern (15/17, 88%) contained a missense TP53 mutation; while the majority of BCs with a null pattern (12/14, 86%) contained a truncating mutation (p < 0.0001). The BCs with a null pattern are associated with a high Nottingham histological grade and a triple-negative phenotype when compared to those demonstrating overexpression (p < 0.05). Conclusion: These findings suggest that p53 IHC can be a potential surrogate for TP53 mutations in BC. Different p53 expression patterns may correlate with specific TP53 genetic mutations in BC.Keywords
This publication has 25 references indexed in Scilit:
- Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer familiesJournal of Medical Genetics, 2015
- Next-generation sequencing in breast cancerCurrent Opinion in Oncology, 2012
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Archives of Pathology & Laboratory Medicine, 2010
- Screening the human exome: a comparison of whole genome and whole transcriptome sequencingGenome Biology, 2010
- A comparison between p53 accumulation determined by immunohistochemistry andTP53mutations as prognostic variables in tumours from breast cancer patientsActa Oncologica, 2008
- TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomesOncogene, 2007
- p53 alterations in human cancer: more questions than answersOncogene, 2007
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Archives of Pathology & Laboratory Medicine, 2007
- Spectrum of p53 Tumor Suppressor Gene Mutations and Breast Cancer SurvivalBreast Cancer Research and Treatment, 2004
- Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patientsBreast Cancer Research, 2000